Breaking News - High Court of Australia Confirms That Methods of Medical Treatment are Patentable

by K&L Gates LLP
Contact

The High Court of Australia yesterday issued its long awaited decision in a dispute between Apotex Pty Ltd (Apotex) and Sanofi-Aventis Australia Pty Ltd and related entities (collectively, Sanofi) concerning Sanofi's Australian patent no. 670491 entitled "Pharmaceutical for the treatment of skin disorders" (Patent). In summary:

  1. The majority (French CJ, Crennan, Keifel and Gageler JJ, Hayne J dissenting) held that assuming all other requirements for patentability are met, a method (or process) for medical treatment of the human body can be a "manner of manufacture" and therefore patentable for the purposes of section 18 of the Patents Act 1990 (Cth) (Act).
  2. The Court unanimously held that Apotex did not indirectly infringe the Patent pursuant to section 117 of the Act by supplying Apo-Leflunomide. It was not shown, nor could it be inferred, that Apotex had reason to believe that Apo-Leflunomide would be used in accordance with the patented method, and Apotex's approved product information document did not instruct recipients to use Apo-Leflunomide in accordance with the patented method.

Background
The dispute concerned Leflunomide, a drug used to treat the skin disorder psoriasis. The patent for the substance Leflunomide expired in 2004. The Patent claims a method of using Leflunomide to treat psoriasis.

Apotex registered its generic, Apo-Leflunomide on the ARTG. Apo-Leflunomide was indicated on the Australian Register of Therapeutic Goods (ARTG) for treatment of rheumatoid arthritis and psoriatic arthritis. Importantly, psoriasis and psoriatic arthritis are separate conditions, but most people with psoriatic arthritis will develop psoriasis. The product information for the product expressly excluded use of the product to treat psoriasis.

Sanofi successfully restrained Apotex from supplying products containing Leflunomide in the Federal Court of Australia. Justice Jagot held that supplying Apo-Leflunomide would infringe the patent for the purposes of section 117(2)(c) of the Act, on the basis that using Leflunomide to treat psoriatic arthritis would inevitably treat (or prevent) psoriasis as well, even if Leflunomide was only prescribed for treating psoriatic arthritis.

The Full Federal Court upheld infringement, but on the basis that Apotex had reason to believe that the product would be put to the infringing use because it accepted that rheumatologists do seek, and will seek, to treat both conditions when patients present with psoriatic arthritis and psoriasis concurrently.

High Court Appeal Manner of manufacture
The majority of the Court held that the Patent was valid.

This was the first time the High Court has considered whether a method of treatment was inherently patentable subject matter, and the majority's decision will have far reaching implications for operators in the pharmaceutical industry.

Importantly, Justices Crennan and Kiefel JJ did draw a distinction between a method of medical treatment which involves a therapeutic use of a pharmaceutical substance, and the activities of doctors or other medical staff when physically treating patients. Such activities or procedures are unlikely to satisfy the test for patentability because they are not capable of being practically applied in commerce or industry, which is a necessary prerequisite for a "manner of manufacture".

High Court Appeal – Indirect infringement
In its application for special leave (heard in December 2012), Apotex also sought leave to appeal the Federal Court's decision regarding whether, its conduct constituted contributory infringement of the Patent pursuant to section 117(1) of the Act.

The Court found that Apotex did not indirectly infringe the Patent by its supply of Apo-Leflunomide. The Court found that Apotex had no reason to believe Apo-Leflunomide would be used to infringe the Patent and nor did it instruct those to whom it supplied the product to do so. This was especially where the entry for Apo-Leflunomide on the ARTG stated that it is a therapeutic good registered for its indicated uses, which specifically excludes use of the method disclosed in the Patent.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© K&L Gates LLP | Attorney Advertising

Written by:

K&L Gates LLP
Contact
more
less

K&L Gates LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.